Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Cell Impact in connection with its fully guaranteed rights issue of SEK 349 million
Mandate

Vinge advises Cell Impact in connection with its fully guaranteed rights issue of SEK 349 million

December 01, 2021 Capital Markets and Public M&A

Vinge advises Cell Impact AB (publ) in connection with a fully guaranteed rights issue which will provide Cell Impact with gross issue proceeds of SEK 349 million

Cell Impact is a global supplier of advanced flow plates to fuel cell manufacturers. The company has developed and patented a unique scalable method for high-velocity forming, Cell Impact Forming™, which makes it possible to produce flow plates with more advanced designs, which in turn creates more cost and energy-efficient fuel cells compared to conventional forming methods.

Vinge’s team consisted of Johan Larsson, Dain Hård Nevonen, Anna Jonsson, Rikard Lindahl, Joel Magnusson and Lorin Arabi.

 

Related

Vinge advised Precise Biometrics

 Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

 Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026